Compass Therapeutics, Inc.
NASDAQ:CMPXBiotechnology
-$0.03 today
- Market cap
- $109.26M
- Beta
- 0.74
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.37
Volume 2.90M
Average 7.64M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Compass Therapeutics, Inc.
NASDAQ:CMPX
Intrinsic Alpha fair value
Locked
Current Price
$0.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A11 analysts |
| Revenue | N/A | N/A | N/A | N/A12 analysts |
| Net Income | N/A | N/A | N/A | N/A12 analysts |
| EBIT | N/A | N/A | N/A | N/A12 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
KalVista Pharmaceuticals, Inc. NASDAQ:KALV | $1.44B | $27.00 | Not rated | -9.9 | +89.21% |
Omeros Corporation NASDAQ:OMER | $1.27B | $17.49 | Not rated | 8.4 | +63.76% |
Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | $897.52M | $10.64 | Not rated | -24.1 | +11.88% |
Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX | $796.97M | $1.79 | Not rated | -30.5 | +21.09% |
4D Molecular Therapeutics, Inc. NASDAQ:FDMT | $675.64M | $12.23 | Not rated | -4.0 | +6.94% |
Monopar Therapeutics Inc. NASDAQ:MNPR | $483.28M | $72.00 | Not rated | -37.6 | -11.84% |
Fulcrum Therapeutics, Inc. NASDAQ:FULC | $287.64M | $3.77 | Not rated | -3.6 | -61.46% |
Ocugen, Inc. NASDAQ:OCGN | $280.88M | $0.83 | Not rated | -5.6 | -34.20% |
Bicycle Therapeutics plc NASDAQ:BCYC | $236.22M | $3.37 | Not rated | -1.3 | -50.54% |
Gossamer Bio, Inc. NASDAQ:GOSS | $67.10M | $10.97 | Not rated | -0.2 | +261.97% |
Continue the stock analysis
Jump to another research area for this company.